Previous 10 | Next 10 |
Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones - Phase 3 Mino-Lok® trial proceeding as planned following recommendation by independent Data Monitoring Committee (DMC), highlighting important safety and efficacy signals ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Seeking Alpha wishes our subscribers a beautiful holiday weekend and a Happy Fourth of July! Wall Street Breakfast won't be published with markets closed o...
Gainers: Sequential Brands Group (SQBG) +88%.Alector (ALEC) +50%.TAT Technologies (TATT) +43%.Marin Software (MRIN) +41%.Overseas Shipholding (OSG) +35%.Staffing 360 Solutions (STAF) +31%.Bridgeline Digital (BLIN) +31%.IDT (IDT) +21%.Nortech Systems (NSYS) +19%.Ocean Power Technologies (OPTT)...
Gainers: Alector (ALEC) +69%. Lucira Health (LHDX) +9%. Provention Bio (PRVB) +7%.Losers: Iterum Therapeutics (ITRM) -34%. Arrowhead Pharmaceuticals (ARWR) -26%. Alterity Therapeutics (ATHE) -21%. Citius Pharmaceuticals (CTXR) -20%. TRxADE HEALTH (MEDS) -17%. For fu...
Iterum Therapeutics (ITRM) -41% after FDA identifies deficiencies in sulopenem NDA.Arrowhead Pharmaceuticals (ARWR) -23% after pausing mid-stage AROENaC1001 study in cystic fibrosis.Birks Group (BGI) -13%.Alterity Therapeutics (ATHE) -12%.Kintara Therapeutics (KTRA) -8%.Ci...
Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceuticals (SCPH) +18%.U.S. Silica Holdi...
Shares of Citius Pharmaceuticals (NASDAQ: CTXR) , a clinical-stage biopharmaceutical company, are getting beaten down today after the company released disappointing news regarding its lead candidate, Mino-Lok. Investors, worried that the treatment isn't going anywhere fast, dragged ...
Gainers: Alterity Therapeutics (ATHE) +103%, TRxADE HEALTH (MEDS) +62%, Pulse Biosciences (PLSE) +22%, Spero Therapeutics (SPRO) +12%, Kintara Therapeutics (KTRA) +6%.Losers: Citius Pharmaceuticals (CTXR) -21%, Aligos Therapeutics (A...
Citius Pharmaceuticals (CTXR) announces that the independent Data Monitoring Committee ((DMC)) for the Mino-Lok Phase 3 Pivotal Superiority Trial has recommended to proceed with the trial as planned, following a unblinded data review of safety and efficacy.The DMC did not identify any sa...
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned - DMC interim safety and efficacy review of Mino-Lok® Phase 3 Trial concluded with favorable recommendation to con...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...